PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.68%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-2.68%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-2.79%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
1.20%
Positive EPS growth while TRAW is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
2.99%
Positive diluted EPS growth while TRAW is negative. John Neff might view this as a strong relative advantage in controlling dilution.
3.80%
Slight or no buybacks while TRAW is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
6.10%
Slight or no buyback while TRAW is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
35.18%
OCF growth 1.25-1.5x TRAW's 24.39%. Bruce Berkowitz would see if superior pricing or efficient operations explain the gap.
35.60%
FCF growth 1.25-1.5x TRAW's 24.39%. Bruce Berkowitz would see if capex decisions or cost controls create a cash flow advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13691.29%
Negative 10Y OCF/share CAGR while TRAW stands at 99.60%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
29.84%
Below 50% of TRAW's 99.10%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
58.26%
3Y OCF/share CAGR at 50-75% of TRAW's 96.44%. Martin Whitman would suspect weaker recent execution or product competitiveness.
-7976.92%
Negative 10Y net income/share CAGR while TRAW is at 98.87%. Joel Greenblatt sees a major red flag in long-term profit erosion.
76.35%
5Y net income/share CAGR at 75-90% of TRAW's 98.90%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
62.71%
Positive short-term CAGR while TRAW is negative. John Neff would see a clear advantage in near-term profit trajectory.
1259.19%
10Y equity/share CAGR above 1.5x TRAW's 100.07%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
224.33%
Positive 5Y equity/share CAGR while TRAW is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
-84.52%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.18%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-26.68%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
20.47%
R&D growth drastically higher vs. TRAW's 7.70%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-32.93%
We cut SG&A while TRAW invests at 10.70%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.